SCILEX HOLDING CO
SCILEX HOLDING CO (SCLX): 5 pipeline candidates · 3 upcoming catalysts · ~1 mo cash runway. Updated within the last hour.
BioSniper Score
6-factor signal · derived from public data
1.4 months
D/E -2.20 · 0% dilution
Lead: Approved
5 candidates
3 upcoming, next in ~1787d
2 buys · 10 sells (180d)
A transparent, data-derived signal for SCILEX HOLDING COacross cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$48.8M
Cash
$3.4M
Quarterly Burn
$31.0M
Runway
1.4 mo
Revenue
$8.6M
Cash Runway vs Catalysts
A catalyst falls after projected cash runway — potential financing / dilution risk before it hits.
Pipeline (5 candidates)
Upcoming Catalysts (3)
Loss of exclusivity — patent/exclusivity expiry opens the door to generic or biosimilar competition that can erode revenue.
Loss of exclusivity — patent/exclusivity expiry opens the door to generic or biosimilar competition that can erode revenue.
Loss of exclusivity — patent/exclusivity expiry opens the door to generic or biosimilar competition that can erode revenue.
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
70
Total value held
$7.4M
| Holder | Shares | Value |
|---|---|---|
| vanguard capital management llc | 528,100 | $3.5M |
| armistice capital, llc | 297,706 | $2.0M |
| blackrock, inc. | 102,796 | $685K |
| vanguard fiduciary trust co | 39,658 | $264K |
| renaissance technologies llc | 36,864 | $246K |
| state street corp | 35,376 | $236K |
| xtx topco ltd | 22,606 | $151K |
| northern trust corp | 15,033 | $100K |
| morgan stanley | 11,973 | $80K |
| citigroup inc | 8,954 | $60K |
Showing top 10 of 70 institutional holders of SCILEX HOLDING CO. Sign up for the full 13F holder list and quarter-by-quarter ownership history.
Frequently asked questions
How many drug candidates are in SCILEX HOLDING CO's pipeline?
SCILEX HOLDING CO (SCLX) has 5 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is SCILEX HOLDING CO's lead drug candidate?
SCILEX HOLDING CO's most advanced tracked candidate is gloperba (Approved) for 1 INDICATIONS AND USAGE GLOPERBA ® (colchicine) Oral Solution is indicated for prophylaxis of gout flares in adults. GLOPERBA is indicated for prophylaxis of gout flares in adults ( 1 ). Limitations of use: The safety and effectiveness of GLOPERBA for acute treatment of gout flares during prophylaxis has not been studied. GLOPERBA is not an analgesic medication and should not be used to treat pain from other causes ( 1 ). Limitations of use: The safety and effectiveness of GLOPERBA for acute tre.
What is SCILEX HOLDING CO's next catalyst?
SCILEX HOLDING CO's next tracked catalyst is a Patent_Expiry event — "Patent/Exclusivity Expiry: ZTLIDO" — expected May 10, 2031.
What is SCILEX HOLDING CO's cash runway?
Based on its most recent reported cash balance and quarterly burn rate, SCILEX HOLDING CO has approximately 1.4 months of cash runway.
What is SCILEX HOLDING CO's market capitalization?
SCILEX HOLDING CO's market capitalization is approximately $48.8M.
Get the full picture on SCILEX HOLDING CO
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.